MyrnaRitaNahasMD
Hematology • Boston, MAHematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Medical Director, Clinical Development
Dr. Nahas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
BIDMC
Boston, MA 02215- Is this information wrong?
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2013 - 2016
UCLA David Geffen School of Medicine/UCLA Medical CenterChief Residency, Internal Medicine, 2012 - 2013- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2009 - 2012
The University of Texas Health Science Center at San AntonioClass of 2009
Certifications & Licensure
CA State Medical License 2011 - 2025
MA State Medical License 2014 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Ruxolitinib + Allogeneic Stem Cell Transplantation in AML Start of enrollment: 2017 Nov 03
- Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma Start of enrollment: 2019 Feb 22
- Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts Start of enrollment: 2019 Aug 01
Publications & Presentations
PubMed
- A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma.Palomba, M., Ray, M., Limbrick-Oldfield, E., Owen, J., Kanters, S., Bobillo, S., Ribiero, M., Ghesquieres, H., Patel, A., Gribben, J., Ghione, P., Jacobson, C., Neelap...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Jan 24
- 5 citationsTreatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study.Paola Ghione, M Lia Palomba, Hervé Ghesquieres, Sabela Bobillo, Anik R Patel, Myrna Nahas, Steve Kanters, Kevin Deighton, Anthony Hatswell, Long Ma, Eve H Limbrick-Old...> ;Haematologica. 2023 Mar 1
- 5 citationsA 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.M Lia Palomba, Paola Ghione, Anik R Patel, Myrna Nahas, Sara Beygi, Anthony J Hatswell, Steve Kanters, Eve H Limbrick-Oldfield, Sally W Wade, Markqayne D Ray, Jessica ...> ;Expert Review of Anticancer Therapy. 2023 Feb 1
- Join now to see all
Abstracts/Posters
- Development of Novel Second Generation DC/Tumor Fusion Vaccine in LymphomaMyrna Nahas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- T Cells Educated By DC/AML Fusions in the Context of 4-1BB Costimulation As a Potent Strategy for Adoptive Cellular TherapyMyrna Nahas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...Myrna Nahas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
Ruxolitinib + Allogeneic Stem Cell Transplantation in AMLSeptember 18th, 2017
Hospital Affiliations
Beth Israel Deaconess Medical CenterBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
